Appendix 1: Information required for UK applications to the MHRA

Information for competent authorities1

Core information

  • Receipt of confirmation of EUDRACT number (obtained from the EUDRACT database)
  • Covering letter
  • Application Form
  • Protocol with all current amendments
  • Investigator's brochure
  • Investigational Medicinal Product Dossier (IMPD)
  • Simplified IMPD for known products
  • Summary of Product Characteristics (SmPC) (for products with marketing authorisation in the Community)
  • List of Competent Authorities to which the application has been submitted and details of decisions
  • Copy of ethics committee opinion when available

MS specific information

Protocol related

  • Summary of the protocol in the national language
  • Outline of all active trials with the same IMP

IMP related

If IMP manufactured in EU:

  • Copy of the manufacturer authorization referred to in Art. 13.1. of the Directive stating the scope of this authorization

If IMP not manufactured in EU:

  • Declaration of the QP that the manufacturing site works in compliance with GMP at least equivalent to EU GMP (see A)
  • Copy of the importer authorization as referred to in Art. 13.1. of the Directive

Certificate of analysis for test product in exceptional cases

  • Summary of the protocol in the national language
  • Certificate of analysis for test product where impurities are not justified by the specification (see A)
  • Viral safety studies
  • Examples of the label in the national language
  • Applicable authorisations to cover trials or products with special characteristics (if available) e.g. GMOs, radiopharmaceuticals
  • TSE Certificate when applicable
  • Declaration of GMP status of active biological substance
  • Manufacturing license when applicable (see B)

A. If not available at the time of submission of the application, should be provided before the study begins

B. On request

References

  1. European Commission Enterprise Directorate-General: Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial, April 2002.


In this section